Price
CHART BY
Frequently asked questions
What is Taysha Gene's market capitalization?
The market capitalization of Taysha Gene is $1.88B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Taysha Gene?
Taysha Gene's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.432. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Taysha Gene's stock?
Currently, 12 analysts cover Taysha Gene's stock, with a consensus target price of $13.33. Analyst ratings provide insights into the stock's expected performance.
What is Taysha Gene's revenue over the trailing twelve months?
Over the trailing twelve months, Taysha Gene reported a revenue of $5.49M.
What is the EBITDA for Taysha Gene?
Taysha Gene's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$155.42M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Taysha Gene?
Taysha Gene has a free cash flow of -$132.57M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Taysha Gene have, and what sector and industry does it belong to?
Taysha Gene employs approximately 99 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Taysha Gene's shares?
The free float of Taysha Gene is 264.37M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.88B
- EPS (TTM)
- -$0.432
- Free Float
- 264.37M
- Revenue (TTM)
- $5.49M
- EBITDA (TTM)
- -$155.42M
- Free Cashflow (TTM)
- -$132.57M
Pricing
- 52W span
- $2.72$7.30
Analyst Ratings
The price target is $13.33 and the stock is covered by 12 analysts.
Buy
12
Hold
0
Sell
0
Information
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
- Employees
- 99
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- TSHA
Fundamentals & EOD data from FactSet